The transition from bare-metal stents (BMS) to drug-eluting stents (DES) in the early 2000s dramatically improved the outcomes from percutaneous coronary intervention (PCI). Although the current generation of DESs yields excellent outcomes, the risk of very late stent thrombosis and late neoatherosclerosis, with their associated unpredictability and high mortality, persists. [ ] Bioresorbable scaffolds (BRS) were designed to overcome some of the limitations of metallic stents, such as the permanent metallic “cage effect”, which precludes coronary vasomotion and pulsatility, as well as mechanical transduction, vessel remodeling and late luminal enlargement. Furthermore coronary artery bypass anastomoses are mechanically impeded in stented segments. [ ]